Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial

X
Trial Profile

European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Baricitinib (Primary) ; Bemcentinib (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Acronyms Bari-SolidAct; EU-SolidAct; SolidAct
  • Most Recent Events

    • 02 Feb 2023 Status changed from recruiting to discontinued.
    • 27 Sep 2022 According to BerGenBio media release, the first patient has been included in a study of BerGenBios oral, highly selective AXL inhibitor, bemcentinib, as part of this EU-SolidAct trial in hospitalized COVID-19 patients
    • 26 Jan 2022 According to BerGenBio media release, EU-SolidAct has established clinical sites in 15 countries. The trial is sponsored by Oslo University Hospital, Norway in collaboration with the Institut National de la Sante Et de la Recherche Medicale (Inserm), France and the not-for-profit intergovernmental organization European Clinical Research Infrastructure Network (ECRIN). The EU-SolidAct trial is part of EU-RESPONSE.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top